Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer

Abstract Mutant KRAS is a key driver in colorectal cancer (CRC) and promotes Myc translation and Myc-dependent stress adaptation and proliferation. Here, we report that the combination of two FDA-approved drugs Bortezomib and Everolimus (RAD001) (BR) is highly efficacious against mutant KRAS CRC cel...

Descripció completa

Dades bibliogràfiques

Autors principals:	Hang Ruan, Brian J. Leibowitz, Yingpeng Peng, Lin Shen, Lujia Chen, Charlie Kuang, Robert E. Schoen, Xinghua Lu, Lin Zhang, Jian Yu
Format:	Artigo
Idioma:	Inglês
Publicat:	Springer 2022-03-01
Col·lecció:	Molecular Biomedicine
Matèries:	Mutant KRAS Myc eIF2α Colorectal cancer Everolimus Bortezomib
Accés en línia:	https://doi.org/10.1186/s43556-022-00070-7
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!